18.49
1.58 (9.34%)
| 前收盘价格 | 16.91 |
| 收盘价格 | 16.92 |
| 成交量 | 1,860,359 |
| 平均成交量 (3个月) | 3,093,068 |
| 市值 | 839,560,640 |
| 价格/销量 (P/S) | 18.04 |
| 股市价格/股市净资产 (P/B) | 7.80 |
| 52周波幅 | |
| 利润日期 | 13 Nov 2024 |
| 营业毛利率 | -146.86% |
| 营业利益率 (TTM) | -575.24% |
| 稀释每股收益 (EPS TTM) | -1.02 |
| 季度收入增长率 (YOY) | -63.40% |
| 总债务/股东权益 (D/E MRQ) | 15.97% |
| 流动比率 (MRQ) | 1.37 |
| 营业现金流 (OCF TTM) | -33.95 M |
| 杠杆自由现金流 (LFCF TTM) | -23.55 M |
| 资产报酬率 (ROA TTM) | -44.49% |
| 股东权益报酬率 (ROE TTM) | -392.69% |
市场趋势
| 短期 | 中期 | ||
| 行业 | Biotechnology (US) | 混合的 | 混合的 |
| Biotechnology (全球的) | 混合的 | 混合的 | |
| 股票 | Capricor Therapeutics, Inc. | 看涨 | 看跌 |
AIStockmoo 评分
| 分析师共识 | 3.0 |
| 内部交易活动 | NA |
| 价格波动 | -0.5 |
| 技术平均移动指标 | -1.0 |
| 技术振荡指标 | -0.5 |
| 平均 | 0.25 |
|
Capricor Therapeutics Inc is a biotechnology company focused on advancing transformative cell and exosome-based therapeutics to redefine the treatment landscape for rare diseases. The company's product pipeline includes CAP-1002, deramiocel an allogeneic cardiac-derived cell therapy. Deramiocel is currently advancing through Phase 3 clinical development for the treatment of Duchenne muscular dystrophy. Through its proprietary StealthXTM platform, the group uses its exosome technology to conduct preclinical research focused on vaccinology, delivering oligonucleotides, proteins, and small molecules to treat and prevent a wide range of diseases with targeted delivery. |
|
| 部门 | Healthcare |
| 行业 | Biotechnology |
| 投资方式 | Small Growth |
| 内部持股比例 | 16.75% |
| 机构持股比例 | 18.53% |
所有权
| 姓名 | 日期 | 持有股份 |
|---|---|---|
| Superstring Capital Management Lp | 30 Sep 2024 | 337,347 |
| 52周波幅 | ||
| 目标价格波幅 | ||
| 高 | 77.00 (HC Wainwright & Co., 316.44%) | 购买 |
| 中 | 37.50 (102.81%) | |
| 低 | 25.00 (Maxim Group, 35.21%) | 购买 |
| 平均值 | 41.67 (125.37%) | |
| 总计 | 6 购买 | |
| 平均价格@调整类型 | 16.10 | |
| 公司 | 日期 | 目标价格 | 调整类型 | 价格@调整类型 |
|---|---|---|---|---|
| Jones Trading | 18 Nov 2024 | 40.00 (116.33%) | 购买 | 18.38 |
| Cantor Fitzgerald | 14 Nov 2024 | 30.00 (62.25%) | 购买 | 18.49 |
| HC Wainwright & Co. | 14 Nov 2024 | 77.00 (316.44%) | 购买 | 18.49 |
| 11 Oct 2024 | 77.00 (316.44%) | 购买 | 17.77 | |
| Piper Sandler | 21 Oct 2024 | 35.00 (89.29%) | 购买 | 20.57 |
| Maxim Group | 25 Sep 2024 | 25.00 (35.21%) | 购买 | 10.34 |
| Oppenheimer | 25 Sep 2024 | 43.00 (132.56%) | 购买 | 10.34 |
| 23 Sep 2024 | 15.00 (-18.88%) | 购买 | 5.97 |
该时间范围内无数据。
支撑、阻力和趋势线水平是由人工智能（AI）模型生成的，请谨慎解读。
投资组合